Supplementary Table 1

Summary of 12 patients in the cohort A

Supplementary Table 2

Summary of mtDNA mutations in the cohort A

Supplementary Table 3

Characteristics of patients treated without ICI for mtDNA sequencing from FFPE samples

Performance status, Eastern Cooperative Oncology Group Performance Status; NE, not evaluated. ¶adenocarcinoma vs. squamous; ¶¶Driver mutation, *EGFR* or *ALK*; ¶¶¶CR or PR or SD vs. PD. The relationships between groups were compared using Fisher’s exact test or two-sided t-test.

Supplementary Table 4

Summary of mtDNA mutations in the cohorts B and C1/2

Supplementary Table 5

Summary of primers for PCR

PCR, polymerase chain reaction; MT, mitochondria

Supplementary Table 6

Summary of antibodies and Live/dead staining used in flow cytometry and western blotting 7-AAD, 7-Amino-Actinomycin D; FC, flow cytometry; WB, Western blotting